Gapping up
In reaction to earnings/guidance:
- DOV +3.7%, TRV +3.3%, FNB +3.1%, STLD +2.4%, SNV +1.1%, IRDM +1%
Other news:
- ETTX +14.1% (announces positive topline results for Phase 3 ATTACK trial)
- HRMY +13.8% (to join S&P SmallCap 600)
- WVE +8% (amends collaboration with TAK)
- BMRA +6.5% (Biomerica announces that Walmart (WMT) has begun in-store sales and rollout of the Company's EZ Detect colorectal disease screening test within the nationwide Walmart retail system)
- UAVS +4.7% (acquires Parrot for $23 mln)
- DRNA +3.4% (announces results for PHYOX4 single-dose study of nedosiran in primary hyperoxaluria type 3)
- VERO +3% (has received 510(k) clearance from the FDA to market the Venus Freedom device)
- UPST +2.2% (BHLB announces partnership with UPST)
- SAGE +2.1% (SAGE Therapeutics and Biogen (BIIB) announce plans to submit a new drug application for Zuranolone to the FDA in the second half of 2022)
- TREE +2% (to move to the S&P SmallCap 600 from S&P MidCap 400)
- BTG +2% (reports Q3 production)
- PRTK +1.7% (first patient has been enrolled in its Phase 2b study of NUZYRA)
- CELC +1.2% (PBYI CELC and Univ of Rochester announce trial collaboration to study patients with breast cancer brain metastases)
- ENTA +1.1% (reports new preclinical data for EDP-235 its recently announced lead oral protease inhibitor specifically designed for the treatment of COVID-19)
- FTI +1% (FTI announces strategic alliance with TALO to provide carbon capture and storage)
Analyst comments:
- ALB +1.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- CCI +1.1% (upgraded to Outperform from Neutral at Credit Suisse)